Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Celldex Therapeutics, Inc.

Market Cap 2.55B 2.22B 2.04B 1.92B 3.6B 240B 3.62B 24.32B 9.45B 118B 9.55B 9.35B 410B P/E 2026 *
-7.47x
P/E 2027 * -7.42x
Enterprise Value 1.96B 1.71B 1.58B 1.48B 2.77B 185B 2.79B 18.74B 7.28B 91.1B 7.36B 7.2B 316B EV / Sales 2026 *
744x
EV / Sales 2027 * 170x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
1 day-1.52%
1 week+8.24%
Current month+3.18%
1 month+7.31%
3 months+13.63%
6 months+28.23%
Current year+19.40%
1 week 31.05
Extreme 31.05
34.14
1 month 28.38
Extreme 28.38
34.14
Current year 22.33
Extreme 22.33
35.79
1 year 19.52
Extreme 19.52
35.79
3 years 14.4
Extreme 14.4
53.18
5 years 14.4
Extreme 14.4
57.2
10 years 1.5
Extreme 1.5
75.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Date Insider Type Main position Quantity % Market Cap.
01-02Fiscal year

Chief Financial Officer

9,634 0.0145%
12-15Fiscal year

Executive/Senior Manager

38,666 0.0582%
12-04Sell

General Counsel

4,166 0.0063%
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%+8.24%+55.76%-9.11% 2.58B
-0.34%-0.08%-12.15%-13.39% 43.44B
+3.31%+9.22%+308.19%+562.02% 33.54B
+2.84%+3.80%+6.87%+34.93% 29.2B
-1.70%-7.34%+8.51%-22.34% 28.48B
-0.57%+4.45%+12.31%+20.42% 25.34B
-0.14%+7.06% - - 14.36B
+0.68%-3.13%+52.04%+107.47% 13.05B
+0.54%-2.27%+3.93%+2.24% 12.67B
-0.26%+0.41%+100.27%+80.69% 12.28B
Average +0.28%+2.06%+59.53%+84.77% 21.5B
Weighted average by Cap. +0.57%+1.49%+63.16%+107.53%

Financials

2026 *2027 *
Net sales 2.63M 2.3M 2.12M 1.99M 3.72M 248M 3.75M 25.18M 9.78M 122M 9.89M 9.68M 424M 11.96M 10.42M 9.61M 9.04M 16.91M 1.13B 17.03M 114M 44.39M 556M 44.9M 43.94M 1.93B
Net income -330M -288M -265M -249M -466M -31.11B -470M -3.15B -1.22B -15.33B -1.24B -1.21B -53.13B -370M -323M -298M -280M -524M -34.92B -527M -3.54B -1.37B -17.21B -1.39B -1.36B -59.64B
Net Debt -584M -509M -469M -441M -826M -55.05B -831M -5.58B -2.17B -27.13B -2.19B -2.15B -94.03B -507M -442M -408M -383M -717M -47.82B -722M -4.85B -1.88B -23.57B -1.9B -1.86B -81.68B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
198
Date Price Change Volume
18/06/26 32.43 $ -1.52% 2,378,401
17/06/26 32.93 $ +1.89% 991,670
16/06/26 32.32 $ +0.62% 999,434
15/06/26 32.12 $ +2.72% 1,007,164
12/06/26 31.27 $ +4.37% 599,806
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
32.43USD
Average target price
57.53USD
Spread / Average Target
+77.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLDX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!